 PRINCETON, N.J.--BUSINESS WIRE--UroGen Pharma Ltd. Nasdaq: URGN, a biopharmaceutical company dedicated to building and commercializing novel solutions that treat specialty cancers and urologic diseases, today announced a strategic, exploratory immunotherapy sponsored research agreement with the Johns Hopkins University to study the potential of checkpoint inhibitors combined with RTGelTM in glioblastoma multiforme, or GBM, an aggressive and difficult to treat brain cancer. Johns Hopkins rese 